drugset / Trial / NCT00902356
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to determine the safety and tolerability of AMG 167 following a single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and postmenopausal women.
Timeline
- Start
- 2009-05
- Primary completion
- 2009-11
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | AMG 167 | Unknown | 21 mg | Subcutaneous |
| Comparator | AMG 167 | Unknown | 70 mg | Subcutaneous |
| Comparator | AMG 167 | Unknown | 210 mg | Subcutaneous |
| Comparator | AMG 167 | Unknown | 350 mg | Subcutaneous |
| Comparator | AMG 167 | Unknown | 700 mg | Subcutaneous |